Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase for late-window acute ischemic stroke before transfer for thrombectomy
2026-525280-40-00Phase 3Authorised
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tenecteplase in ischemic stroke (2 arms), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Primary functional outcome at 90 days (ordinal mRS). Planned start Aug 2026; status: authorised.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2026-525280-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525280-40-00.